Clinical Trials Browser

Phase 1/2 × OTHER × TPI-287 × Clear all

NCT01505608 2024-08-06

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Phase 1/2 Terminated

14 enrolled 11 charts

Neuroblastoma

NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Phase 1/2 Terminated

12 enrolled 7 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Phase 1/2 Withdrawn

Melanoma, Recurrence, Disease Progression